immuno-oncology – Talk Bio

Genelux Corporation Appoints Jason Litten, M.D., as Chief Medical Officer to Advance Olvi-Vec Development

3 weeks ago talkbio0Tagged Chief Medical Officer, Chronic multifocal osteomyelitis, Clinical Trials, Genelux Corporation, immuno-oncology, Jason Litten

Genelux Corporation; Jason Litten; Chief Medical Officer; CMO; Olvi-Vec; immuno-oncology; clinical trials

Ankyra Therapeutics Appoints Sailaja Battula, PhD as Chief Scientific Officer

1 month ago talkbio0Tagged Ankyra Therapeutics, Appointments, Biotechnology, CSO, immuno-oncology, Sailaja Battula

Ankyra Therapeutics; Sailaja Battula; CSO appointment; immuno-oncology; biotechnology

‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure

1 month ago talkbio0Tagged Arcus Biosciences, casdatifan, domvanalimab, EDGE-Gastric, Esophageal Neoplasms, Failure (biologic function), Gilead Sciences, immuno-oncology, Malignant neoplasm of stomach, nivolumab, Opdivo, Overall Survival, Phase 3 trial, STAR-221, TIGIT gene, zimberelimab

domvanalimab; TIGIT; Gilead Sciences; Arcus Biosciences; STAR-221; gastric cancer; esophageal cancer; zimberelimab; Opdivo (nivolumab); Phase 3 trial failure; overall survival; casdatifan; immuno-oncology; EDGE-Gastric

Friday Five: ESMO Looms Large, Arcus’ TIGIT Revival, and J&J’s Myeloma Advances

3 months ago talkbio0Tagged 2025, Arcus Biosciences, domvanalimab, ESMO, gastroesophageal adenocarcinoma, immuno-oncology, J&J, Multiple Myeloma, oncology clinical trials, Substance with programmed cell death protein 1 inhibitor mechanism of action (substance), TIGIT antibody, zimberelimab

ESMO 2025; Arcus Biosciences; domvanalimab; TIGIT antibody; gastroesophageal adenocarcinoma; J&J; multiple myeloma; immuno-oncology; PD-1 inhibitor; zimberelimab; oncology clinical trials

Recent News: Gain Peace of Mind with the Lentiviral Experts

4 months ago talkbio0Tagged advanced manufacturing, Biological Factors, CAR-T therapy, gene therapy, Growth, immuno-oncology, lentiviral vectors, Market, regulatory approval

lentiviral vectors; CAR-T therapy; gene therapy; biologics; immuno-oncology; market growth; advanced manufacturing; regulatory approval

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

7 months ago talkbio0Tagged Arcus Biosciences, Clinical Trials, Gilead, immuno-oncology, iTeos, Merck, Myers, Novartis, Pharma, Roche (company), SmithKline Beecham, squibb, TIGIT gene, Tiragolumab

TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug

Recent Developments in Immune Profiling for Early Immuno-Oncology Trials

7 months ago talkbio0Tagged Artificial Intelligence, Biological Markers, Clinical Trials, Discover, immune profiling, immuno-oncology, Immunotherapy, microenvironment, multi-omic strategies, Neoplasms, Precision Medicine, spatial proteomics

immune profiling; immuno-oncology; clinical trials; AI in immunotherapy; multi-omic strategies; tumor microenvironment; spatial proteomics; biomarker discovery; personalized medicine

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

8 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, biotech partnerships, BNT327, immuno-oncology, Malignant Neoplasms, Myers, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; immuno-oncology; cancer; PD-L1; VEGF-A; solid tumors; biotech partnerships

iTeos to Shut Down Operations After TIGIT Therapy Setback

8 months ago talkbio0Tagged asset, belrestotug, Clinical trial failure, ENT1, EOS-215, EOS-984, Exit, Failure (biologic function), immuno-oncology, iTeos, Obesity, Programs - Publication Format, Sales - occupational activity, SmithKline Beecham, TIGIT gene

iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program

GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

9 months ago talkbio0Tagged belrestotug, Clinical Trials, dostarlimab, Drug Development, Galaxies, immuno-oncology, iTeos, Lung-201, Malignant neoplasm of lung, Progression-Free Survival, SmithKline Beecham, TIGIT gene

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival